Tesamorelin
GHRH Analogue for Visceral Fat Research
Tesamorelin is the only FDA-approved GHRH analogue — approved specifically for HIV-associated lipodystrophy (excess visceral fat accumulation). Unlike other secretagogues, it has a targeted, well-defined clinical application with Phase 3 data specifically on visceral adipose tissue reduction, making it a precision tool in metabolic and GH axis research.
At a Glance
Tesamorelin conjugates the full 44-amino-acid GHRH sequence with a trans-3-hexenoic acid group, improving stability and extending half-life. It stimulates pituitary GH release through the GHRH pathway — the same mechanism as sermorelin and CJC-1295, but with FDA-validated efficacy specifically for visceral fat reduction.
The Phase 3 TRHADA and F-TOHE trials demonstrated ~15–18% visceral fat reduction vs placebo over 26 weeks, with sustained effects maintained in long-term extension studies.
Its GHRH pathway mechanism means the same physiological GH ceiling applies as with sermorelin — GH stimulation cannot exceed pituitary capacity, an inherent safety feature.
This compound operates through several converging biological pathways, which helps explain the breadth of effects observed across different tissue and metabolic models.
GHRH Receptor Agonism
Full 44-amino-acid GHRH sequence with stability enhancement — the most complete GHRH analogue in clinical use.
Visceral Fat Reduction
Specifically studied and approved for visceral adipose tissue reduction — the fat depot most associated with metabolic and cardiovascular risk.
GH/IGF-1 Elevation
Consistent GH and IGF-1 elevation via GHRH pathway — physiologically gated by pituitary capacity.
Physiological GH Ceiling
Full GHRH pathway activation means GH release remains within pituitary-determined physiological limits.
- HIV-associated lipodystrophy — FDA-approved indication; Phase 3 trial data
- Visceral adipose tissue reduction — most studied GHRH analogue for VAT outcomes
- Metabolic risk factor improvement — visceral fat's relationship to insulin resistance and CVD
- GH axis restoration in lipodystrophy — mechanistic studies on GH's role in fat distribution
- NAFLD research — visceral fat and liver fat reduction models
- Body composition in aging — VAT accumulation as age-related phenomenon
- Cognitive function — emerging research on GH axis and cognition in aging
Tesamorelin's FDA approval distinguishes it clearly from other GHRH analogues — it's the only one with Phase 3 validation for a specific metabolic indication.
| Aspect | Tesamorelin | Sermorelin | CJC-1295 DAC |
|---|---|---|---|
| Regulatory Status | FDA approved (Egrifta) | Not approved (was, withdrawn) | Not approved |
| Primary Indication | HIV lipodystrophy / VAT | Anti-aging, GH deficiency | Body composition |
| GHRH Sequence | Full 44-AA + conjugated | 29-AA fragment | 29-AA + DAC modification |
| Clinical Data | Phase 3 (substantial) | Phase 3 (historic) | Limited |
| Best Research Use | VAT-specific outcomes | Conservative, long-term | Weekly dosing models |
FDA approved — the only GHRH analogue with regulatory approval and Phase 3 efficacy data
Visceral fat-specific evidence — Phase 3 data on VAT reduction not available for other secretagogues
Long-term safety data — multi-year extension trials provide extended human safety profile
Narrow approved indication — approved specifically for HIV lipodystrophy; research outside this context is off-label
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026